BioSpace News Archive

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), today announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 that took place June 22-26 in London, United Kingdom.

Kezar Life Sciences, Inc. (Nasdaq: KZR), today reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN).

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) people with multi-drug resistant (MDR) HIV-1 infection.

Acerus Pharmaceuticals Corporation announced the voting results from its annual meeting of shareholders held on June 27, 2022.

Biophytis SA announced that it is giving an oral presentation on the development of Sarconeos for the treatment of sarcopenia at the 15th International SCWD Congress.

Astellas Pharma Inc. and Sutro Biopharma, Inc. announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it was selected to present the preclinical data of TST004 at the 2022 ISN Frontiers Meetings of Complement-Related Kidney Diseases in Bergamo, Italy.

Verisante Technology Inc. announces that further to the Company’s announcement of June 5, 2022, it has received final TSX-V Exchange acceptance and will now issue 15,154,182 pre-consolidation common shares at a deemed price of $0.05 per pre-consolidation share to settle $757,709.10 of outstanding debt.

According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Moreover, as per the same source, about 70% of all cancer deaths occur in low- and middle-income countries.